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OBJECTIVE—The T helper 17 (Th17) population, a subset of
CD4-positive T-cells that secrete interleukin (IL)-17, has been
implicated in autoimmune diseases, including multiple sclerosis
and lupus. Therapeutic agents that target the Th17 effector
molecule IL-17 or directly inhibit the Th17 population (IL-25)
have shown promise in animal models of autoimmunity. The role
of Th17 cells in type 1 diabetes has been less clear. The effect of
neutralizing anti–IL-17 and recombinant IL-25 on the develop-
ment of diabetes in NOD mice, a model of spontaneous autoim-
mune diabetes, was investigated in this study.
RESEARCH DESIGN AND METHODS AND RESULTS—
Although treatment with either anti–IL-17 or IL-25 had no effect
on diabetes development in young (5 weeks) NOD mice, either
intervention prevented diabetes when treatment was started at
10 weeks of age (P  0.001). Insulitis scoring and immunoﬂuo-
rescence staining revealed that both anti–IL-17 and IL-25 signif-
icantly reduced peri-islet T-cell inﬁltrates. Both treatments also
decreased GAD65 autoantibody levels. Analysis of pancreatic
lymph nodes revealed that both treatments increased the fre-
quency of regulatory T-cells. Further investigation demonstrated
that IL-25 therapy was superior to anti–IL-17 during mature
diabetes because it promoted a period of remission from new-
onset diabetes in 90% of treated animals. Similarly, IL-25 delayed
recurrent autoimmunity after syngeneic islet transplantation,
whereas anti–IL-17 was of no beneﬁt. GAD65-speciﬁc ELISpot
and CD4-positive adoptive transfer studies showed that IL-25
treatment resulted in a T-cell–mediated dominant protective
effect against autoimmunity.
CONCLUSIONS—These studies suggest that Th17 cells are
involved in the pathogenesis of autoimmune diabetes. Further
development of Th17-targeted therapeutic agents may be of
beneﬁt in this disease. Diabetes 58:1302–1311, 2009
T
ype 1 diabetes is an autoimmune condition asso-
ciated with the T-cell–mediated destruction of
pancreatic -cells. Detailed investigations using
the NOD mouse, a model of spontaneous type 1
diabetes, have indicated that Th1 populations, which are
associated with the transcription factor T-bet and the
secretion of cytokines, including -interferon (IFN-) and
interleukin (IL)-2, are key mediators of -cell autoreactiv-
ity (rev. in 1). Conversely, induction of Th2 populations,
which are associated with the transcription factor GATA-3
and cytokines such as IL-4 and -10, results in a dominant
protective effect against autoimmunity in this model (1).
This paradigm is not speciﬁc to type 1 diabetes; in fact, the
relative pathogenic contributions of Th1 cells and protec-
tive effects of Th2 cells have been described as a common
feature of other organ-speciﬁc autoimmune diseases, in-
cluding multiple sclerosis and rheumatoid arthritis (2–4).
More recently, a new subpopulation of CD4-positive
T-cells has been characterized, the so-called Th17 cells,
which are associated with the transcription factor RORT
and secretion of the proinﬂammatory cytokines IL-17
(IL-17A) and IL-17F (5,6). These cells appear to play a
central role in early inﬂammation and eosinophil recruit-
ment, and their common requirement for transforming
growth factor (TGF)- during activation suggests that this
population has evolved to counteract the inhibitory prop-
erties of the regulatory T (Treg) cell population (7,8).
Although the Th17 population contributes to the normal
inﬂammatory response, it can become dysregulated in the
presence of IL-23, which enhances the stability and sur-
vival of this subpopulation, a feature that has been impli-
cated in the development of autoimmunity (8). Indeed,
studies using IL-17 as a surrogate marker of Th17 activity
have repeatedly associated high levels of IL-17 with most
autoimmune conditions in humans and animal models,
including rheumatoid arthritis (9), inﬂammatory bowel
disease (10), and multiple sclerosis (11). The relative
contribution of Th17 cells in type 1 diabetes has been less
evident. High levels of the IL-17 transcript have been found
within insulitic lesions in NOD mice, and increasing levels
of serum IL-17 were associated with the development of
diabetes in a T-cell receptor transgenic NOD model with
accelerated disease progression (12). More recently, stud-
ies have demonstrated that therapeutic intervention with
an antigen-speciﬁc agent that protects against diabetes in
NOD mice is associated with a decrease in Th17 popula-
tions (13). However, the speciﬁc contribution of Th17 cells
to the natural progression of type 1 diabetes in the NOD
mouse remains to be fully characterized.
In an effort to both understand the impact of and reduce
the negative effects of the Th17 subpopulation, a number
of studies have been carried out using neutralizing anti–
IL-17 antibodies. A single injection of anti–IL-17 antibody
prevented inﬂammation and bone erosion and reduced
Th17 populations in experimental rheumatoid arthritis
(14), whereas multiple doses of anti–IL-17 over 2 weeks
dramatically reduced inﬂammatory lesions and neurologi-
cal symptoms in experimental autoimmune encephalomy-
elitis (EAE), a model of multiple sclerosis (15). Based on
these studies, anti–IL-17 antibodies (AIN457 [Novartis]
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clinically in autoimmune diseases, including rheumatoid
arthritis, psoriasis, and Crohn’s disease (16). Another
approach to interfere with Th17 populations involves the
use of the cytokine IL-25 (IL-17E), a naturally occurring
cytokine within the IL-17 family that has been shown to
potently inhibit Th17 cells and instead promote the devel-
opment of Th2 responses (17–19). IL-25 knockout mice are
highly susceptible to autoimmunity, with a dramatic in-
crease in Th17 cells using the EAE model (18). This study
also demonstrated that both IL-25 knockout and wild-type
animals could be protected from the deleterious effects of
Th17 cells in EAE when recombinant IL-25 was
administered.
Because Th17 subsets are increasingly considered to be
a key mediator of all autoimmune disease, therapeutic
strategies designed to inhibit these cells are likely to be
applicable in type 1 diabetes. The purpose of the current
study was to investigate the role of Th17 cells in type 1
diabetes using both neutralizing anti–IL-17 antibodies and
recombinant IL-25 in the NOD mouse model.
RESEARCH DESIGN AND METHODS
NOD/LtJ and NOD-RAG
/ mice (NOD.129S7-Rag1
tm1Mom/J) were obtained
from Jackson Labs (Bar Harbor, ME). For remission and transplant studies,
spontaneously diabetic NOD females were identiﬁed by monitoring our colony
two to three times per week, with animals considered diabetic after two
consecutive blood glucose readings 18 mmol/l or one reading 25 mmol/l
with a One Touch Ultra Glucometer (LifeScan, Mississauga, ON, Canada). All
animals were cared for according to the guidelines of the Canadian Council on
Animal Care, and ethical approval was obtained from the animal welfare
committee at the University of Alberta.
Drug therapy. A mouse anti–IL-17 monoclonal antibody (clone 50104),
mouse IgG2A isotype control antibody, and IL-25 (IL-17E) were all obtained
from R&D Systems (Minneapolis, MN).
Diabetes prevention. For studies examining IL-17 neutralization, anti–IL-17
or isotype control was administered at 100 g i.p. on alternating days over a
12-day period (six total injections). For studies using IL-25, the recombinant
cytokine was administered at 1 g s.c. daily for 25 days (an equivalent volume
of saline was given to vehicle-administered animals).
Diabetes remission. Spontaneous diabetic mice were assigned randomly to
one of the following treatment groups: anti–IL-17 (100 g i.p. every other day),
IL-25 (1 mg s.c. daily), or control (IgG at 100 g i.p. for anti–IL-17 and vehicle
for IL-25). Treatment was continued until eight consecutive daily readings
25 mmol/l were obtained, after which point the experiment was terminated.
Diabetes recurrence after syngeneic islet transplantation. For anti–
IL-17 studies, transplanted animals received either anti–IL-17 or isotype
control treatment (100 g i.p.) on days 0, 4, 8, 12, and 16 posttransplant. For
IL-25 studies, transplanted animals received either IL-25 (1 g s.c.) or vehicle
daily through day 15 posttransplant.
Insulitis scoring. At 1 month after the completion of treatment, pancreatic
tissue was harvested, ﬁxed in formaldehyde, processed, and embedded in
parafﬁn (20). Sections (10 m) were stained using hematoxylin and eosin. All
samples were blinded before being scored by a single pathologist using the
scheme outlined by Yoon et al. (21). Representative islets were photographed
using a Zeiss microscope at 200 magniﬁcation.
Immunoﬂuorescence. Before immunostaining, cryostat sections (10 m) of
pancreata were ﬁxed in acetone and blocked using 20% goat serum. Rat
anti-mouse CD4 (clone GK1.5; Ebioscience, Mississauga, ON, Canada), rat
anti-mouse CD8 (clone 53–6.7; Ebioscience), rat anti-mouse Foxp3 (clone
FJK-16s; Ebioscience), and polyclonal guinea pig anti-insulin (Dako, Missis-
sauga, ON, Canada) were used as primary antibodies. To detect bound
antibodies, biotinylated goat anti-rat antibodies (for CD4, CD8, and Foxp3;
Cedarlane) and tetramethylrhodamine isothiocyanate–labeled goat anti–gu-
inea pig antibodies (1:200, for insulin; Cedarlane) were used. Polyclonal rabbit
anti–IL-17 (Cedarlane Labs, Mississauga, ON, Canada) was used to detect
IL-17 on formalin-ﬁxed sections. All slides were mounted using ImmunoGold
mounting medium with 4,6-diamidino-2-phenylindole for nuclear counter-
staining (Invitrogen, Mississauga, ON, Canada).
GAD65 autoantibody assays. Recombinant GAD65 was prepared as previ-
ously described and kindly provided by Dr. John Elliott (22). Serum was
harvested via tail vein bleeds from treated animals, and GAD65 autoantibody
levels were determined using the method described by Ma et al. (23). Serum
samples were diluted 1:50 in blocking buffer. Reactions were stopped after 20
min using 1 mol/l H2SO4 and immediately analyzed at 450-nm wavelength.
Islet transplantation studies. Mouse islets were isolated using established
methods (24). Spontaneously diabetic NOD females were maintained on daily
insulin injections for 2–3 weeks to collect a sufﬁcient cohort to transplant,
with insulin withdrawal the day before islet transplantation. A total of 500
NOD-RAG
/ islets (syngeneic but without insulitis) were transplanted under
the left kidney capsule.
Flow cytometry, enzyme-linked immunosorbent assay, and enzyme-
linked immunospot assays. An enzyme-linked immunosorbent assay
(ELISA) for TGF-1 and enzyme-linked immunospot (ELISpot) kits for IFN-,
IL-4, and IL-17 were purchased from Ebioscience. At 1 month after the
completion of treatment, animals were euthanized, and peripheral blood
mononuclear cells were puriﬁed from spleen or pancreatic lymph nodes using
Lympholyte-M (Cedarlane). An aliquot of cells was stained for Treg cell
activity using the murine CD4/CD25/FoxP3 ﬂow cytometry kit available from
Ebioscience. A total of 1,000,000 splenocytes (or 2  10
5 pancreatic lymph
node cells) were incubated with 20 g/ml GAD65 in RPMI medium supple-
mented with 10% FCS (Invitrogen) for 48 h. After this incubation period,
ELISpot plates were washed and processed according to the manufacturer’s
protocols. Supernatants were harvested for TGF-1 ELISA and processed
according to the manufacturer’s instructions. Developed plates were read
using an ImmunoSpot ELISpot reader, and the total number of spots per well
was quantiﬁed using ImmunoSpot 4.0.17 software (Cellular Technology,
Shaker Heights, OH). Lymphocytes from individual animals in each experi-
mental group were analyzed in triplicate. Four-color ﬂow cytometric analysis
was carried out using Cell Quest Pro (BD Biosciences, Mississauga, ON,
Canada).
Adoptive transfer studies. At 1 month after the completion of treatment,
splenocytes were harvested and puriﬁed with Lympholyte-M. CD4-positive
T-cells were extracted from splenocyte suspensions using magnetic beads
(negative selection; Miltenyi Biotec, Mississauga, ON, Canada) and conﬁrmed
to be 90% pure by ﬂow cytometry (data not shown). Naïve NOD-RAG
/
males received either 1  10
7 splenocytes from a spontaneously diabetic NOD
mouse (“diabetic splenocytes”), 1  10
7 diabetic splenocytes combined with
2  10
6 CD4-positive splenocytes from normoglycemic NOD mice previously
treated with anti–IL-17, or 1  10
7 diabetic splenocytes combined with 2  10
6
CD4-positive splenocytes from normoglycemic NOD mice previously treated
with IL-25. Blood glucose levels were monitored three times per week
thereafter.
Statistics. All statistical analyses in this study were carried out using
SigmaPlot 10 and SigmaStat 3.5 (Systat), and results are expressed as the
means 	 SE. Mann-Whitney rank-sum tests were used, and ANOVA performed
on ranks with Bonferroni post hoc analysis was used to analyze multiple
groups. Kaplan-Meier survival analyses were compared using the log-rank test.
RESULTS
Inhibition of Th17 cells prevents progression to dia-
betes in pre-diabetic animals. To explore the potential
contribution of Th17 cells to the natural development of
type 1 diabetes, either neutralizing anti–IL-17 antibodies or
IL-25 were administered to 5-week-old NOD females to
investigate the role of this population in the initiation
phase of autoimmunity and to 10-week-old NOD females
to investigate the role of Th17 cells during the effector
phase of autoimmunity. Dosing regimens for anti–IL-17
(100 g i.p. days on alternating days for 2 weeks) and IL-25
(1 g s.c. each day for 25 days) were based on results
obtained in the EAE model, which effectively controlled
antigen-speciﬁc Th17 cells (15,18). As shown in Fig. 1A,
IL-17 neutralization did not alter diabetes progression
when treatment was initiated at 5 weeks of age, and a
similar result was obtained using IL-25 beginning at 5
weeks of age (Fig. 1C). In contrast, both anti–IL-17 (Fig.
1B) and IL-25 (Fig. 1D) prevented diabetes development in
the majority of treated animals by 6 months of age when
treatment was initiated at 10 weeks of age (P 
 0.001 by
log-rank test for each group vs. controls; n 
 10 per
group). These data suggest that Th17 cells are involved in
the natural progression of type 1 diabetes, particularly
during the effector phase of disease development.
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inﬂammation. To further understand the mechanism of
diabetes prevention using anti–IL-17 or IL-25 treatment
during the effector phase of type 1 diabetes development,
detailed histological analysis was carried out in normogly-
cemic animals 1 month after the completion of treatment
(serial sections from six to eight animals per group).
Insulitis scoring by a pathologist using blinded samples
indicated that both treatment strategies signiﬁcantly re-
duced the degree of islet inﬂammation (Fig. 2). The
majority of the pancreata in normoglycemic control ani-
mals had destructive insulitis (mean score of 2.6 	 0.3),
whereas insulitis was signiﬁcantly reduced in both anti–
IL-17–treated (mean score 2.0 	 0.3) and IL-25–treated
animals (1.5 	 0.3; P  0.05 for anti–IL-17, and P  0.02 for
IL-25 vs. controls; representative hematoxylin and eosin–
stained sections from each cohort are shown in Fig.
2B–D). To determine the contribution of different T-cell
populations within the peri-islet inﬁltrates in both anti–IL-
17– and IL-25–treated animals, immunoﬂuorescence stain-
ing for CD4, CD8, Foxp3, and IL-17 was carried out in
combination with insulin staining and compared with
control animals. As shown in Fig. 3, insulitic lesions in
normoglycemic control NOD mice were composed primar-
ily of CD4-positive cells, with a smaller proportion of
CD8-positive lymphocytes and low Foxp3 staining. Exam-
ination of multiple sections of control NOD pancreata for
IL-17 staining consistently showed a small number of
IL-17–positive cells within the peri-islet inﬁltrates, regard-
less of the degree of insulitis. Pancreatic sections from
normoglycemic animals treated with either anti–IL-17 or
IL-25 demonstrated a reduced level of insulitis that was
composed primarily of CD4-positive cells, a reduced
number of CD8-positive cells, and enrichment in Foxp3-
positive cells compared with control animals. Very few
IL-17–positive cells were observed in anti–IL-17–treated
animals, with only a small proportion of inﬂamed islets
staining positive for IL-17 (representative sections in Fig.
3). Analysis of multiple sections from IL-25–treated ani-
mals for IL-17 staining did not reveal any IL-17–positive
cells (representative section in Fig. 3). Overall, these data
indicate that inhibition of Th17 cells with both anti–IL-17
and IL-25 treatment regimens signiﬁcantly reduces islet-
speciﬁc inﬂammatory T-cell inﬁltration and increases the
proportion of Foxp3-positive cells around the islets.
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FIG. 1. Inhibition of Th17 cells with either neutralizing anti–IL-17 or IL-25 has no effect when treatment is initiated during the initiation stage
of autoimmune diabetes, but treatment signiﬁcantly reduces the incidence of diabetes when it occurs during the effector stage. The impact of a
neutralizing anti–IL-17 antibody as well as the Th17-inhibitory cytokine IL-25 was investigated during two phases of diabetes development in
NOD mice. Treatment was initiated at either 5 weeks of age, which represents the initiation stage of autoimmunity, as characterized by mild
insulitis, or at 10 weeks of age, when the effector phase of autoimmunity is occurring, and the majority of NODs will have invasive insulitis.
Anti–IL-17 treatment (100 g i.p. on days 0, 2, 4, 6, 8, and 10) did not alter the course of diabetes when it was initiated at 5 weeks of age (A),
whereas treatment initiation at 10 weeks of age (B) resulted in a signiﬁcant increase in the number of nondiabetic animals (P  0.001 by
log-rank). Similar results were obtained with recombinant IL-25, which had no effect when treatment was started at 5 weeks of age (C) but
signiﬁcantly increased diabetes-free survival at 10 weeks of age (D)( P  0.001 by log-rank).
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toantibody formation. Inhibition of Th17 populations in
other models of autoimmunity has resulted in a measur-
able reduction in autoantibody formation (25,26). To de-
termine the impact of anti–IL-17 and IL-25 therapies on
autoreactive B-cells in NOD mice, serum samples were
analyzed for anti-GAD65 autoantibodies, a later-stage
marker of autoimmunity in this model (27). Initially, serum
samples obtained from anti–IL-17– and IL-25–treated ani-
mals 1 month after the completion of treatment (effector
phase) were analyzed, and a signiﬁcant reduction in
GAD65 autoantibodies was observed in both anti–IL-17–
treated (mean optical density 1.11 	 0.02) and IL-25–
treated (1.03 	 0.03) animals compared with controls
(1.34 	 0.08; P  0.02 vs. anti–IL-17, and P  0.005 vs. IL-25
by ANOVA) (Fig. 4A). Based on these data, we chose to
prospectively monitor IL-25–treated animals for GAD65
autoantibody levels to determine whether this observation
persisted over time (serum samples were not collected
prospectively in anti–IL-17 studies and thus could not be
analyzed). Animals treated with IL-25 exhibited a persis-
tent reduction in GAD65 autoantibody formation up to 90
days after the completion of treatment (P  0.001 vs.
control by ANOVA). These data indicate that inhibition of
Th17 cells in type 1 diabetes can prevent autoantibody
formation.
IL-25, but not anti–IL-17, treatment restores eugly-
cemia in newly diabetic mice and delays recurrent
autoimmunity after syngeneic islet transplantation.
In the NOD mouse model, the initiation and effector
phases of disease, before the onset of hyperglycemia,
carry the lowest threshold for disease prevention (rev.
in 28). However, once the autoimmune response has
matured and resulted in hyperglycemia, reversal of
diabetes and prevention of recurrent autoimmunity af-
ter -cell replacement represent signiﬁcant barriers,
with only a few therapeutic strategies regulating type 1
diabetes in the NOD mouse at these late-stage disease
time points (28). Thus, to understand the role of Th17
cells after the development of overt diabetes, a series of
experiments were conducted in two different models: at
the time of diabetes onset (attempt to reverse new-onset
diabetes) and after a period of rest after diabetes onset
with subsequent -cell replacement via syngeneic islet
transplantation (recurrent autoimmunity). Data in Fig.
5A illustrates that anti–IL-17 had no effect once diabetes
was established, with all animals remaining persistently
diabetic throughout the treatment period. However,
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FIG. 2. Both anti–IL-17 and IL-25 reduced the degree of insulitis in treated animals. A: Pancreata from anti–IL-17–treated, IL-25–treated, and
control animals were harvested 1 month after the completion of treatment and stained with hematoxylin and eosin. The slides were blinded and
scored by a pathologist according to the following scale (based on >50% of the islets in that section exhibiting the associated pattern): 0 (no
inﬁltrate), 1 (mild peri-islet inﬁltrate), 2 (invasive insulitis with 25–50% islet destruction), and 3 (destructive insulitis with >50% islet
destruction). Both anti–IL-17 (mean score 2.03  0.33) and IL-25 (mean score 1.50  0.33) treatment markedly reduced insulitis compared with
controls (mean score 2.63  0.26, P < 0.05 for anti–IL-17 vs. control and P < 0.02 for IL-25 vs. control by ANOVA). B–D: Representative
hematoxylin- and eosin-stained islets from each cohort (control [B], anti–IL-17 [C], and IL-25 [D]) are presented at 200 magniﬁcation. (A
high-quality digital representation of this ﬁgure is available in the online issue.)
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of treated animals, versus none of the controls (P 
0.0001 by ANOVA, and P 
 0.002 by Fisher’s exact test)
(Fig. 5B). Ultimately, most animals returned to hyper-
glycemia by 10 days after initiation of treatment, despite
ongoing therapy, although one animal did exhibit per-
sistent normoglycemia for 100 days even after IL-25
treatment withdrawal at day 30 (data not shown). This
enhanced efﬁcacy of IL-25 compared with anti–IL-17
was also observed in recurrent autoimmunity after
syngeneic islet transplantation, where IL-25 nearly dou-
bled islet graft survival time from 4.2 	 0.8 days in
control animals to 7.2 	 0.2 days in treated animals (P 

0.0013 by log-rank test). These studies indicate that
IL-25, which is known to directly inhibit Th17 popula-
tions, is superior to IL-17 neutralization in regulating a
mature autoimmune response after the onset of
hyperglycemia.
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representation of this ﬁgure is available in the online issue.)
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FIG. 4. Treatment with anti–IL-17 or IL-25 prevents GAD65 autoantibody formation. Serum samples were collected in anti–IL-17–treated,
IL-25–treated, and control animals 1 month after the completion of treatment and analyzed for GAD65 autoantibodies using an ELISA. A: Both
anti–IL-17 and IL-25 treatment regimens were associated with a signiﬁcant reduction in the number of GAD65 IgG antibodies compared with
control animals (P < 0.02 for anti–IL-17 vs. control and P < 0.005 for IL-25 vs. control by ANOVA). B: Animals treated with IL-25 were followed
prospectively for GAD65 autoantibody development, and this treatment effectively prevented autoantibody formation >90 days after the
initiation of treatment (P < 0.001 by ANOVA). A minimum of n  4 animals were analyzed at each time point. OD, optical density.
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tive Th2 and Th17 T-cells and results in the de-
velopment of a Treg-enriched CD4-positive T-cell
population that dominantly protects against disease
transfer. Although both anti–IL-17 and IL-25 therapies
were able to reduce the incidence of type 1 diabetes during
the effector phase leading into type 1 diabetes, only IL-25
therapy was able to control diabetes once the disease was
established. To further investigate the different mecha-
nisms by which these two therapies function, splenocytes
from normoglycemic treated animals in the prevention
studies (Fig. 1) were examined ex vivo for autoreactive
T-cell populations using GAD65-stimulated ELISpot assays
at 1 month after the completion of treatment. Although no
difference in IFN-–secreting GAD65-responsive spleno-
cytes was observed compared with controls (Fig. 6A), a
signiﬁcant reduction in IL-4–secreting GAD65-responsive
splenocytes was observed in IL-25–treated animals com-
pared with both anti–IL-17–treated and control animals
(P  0.02) (Fig. 6B). Paradoxically, anti–IL-17 treatment
resulted in an increased frequency of IL-17–secreting
GAD65-reponsive splenocytes, whereas the opposite oc-
curred after IL-25 treatment, where a signiﬁcant reduction
in this autoreactive Th17 population was observed (P 
0.001 for anti–IL-17 vs. control and IL-25, and P  0.05 by
ANOVA for IL-25 vs. control) (Fig. 6C).
Next, a series of adoptive transfer experiments was
carried out using immunodeﬁcient NOD-RAG
/ recipi-
ents. In this model, transfer of 1  10
7 splenocytes from a
recent-onset diabetic NOD mouse results in hyperglycemia
in all recipients (control mean diabetes onset at 42.8 	 2.3
days post-transfer) (Fig. 6D). To evaluate whether the
protective effects of anti–IL-17 or IL-25 treatment could
dominantly control autoreactive T-cell populations, 2 
10
6 puriﬁed CD4-positive splenic T-cells, harvested from
either anti–IL-17 or IL-25 treated animals 1 month after the
completion of treatment, were coinjected with 1  10
7
diabetic splenocytes into naïve normoglycemic NOD-
RAG
/ recipients. In these experiments, cotransfer of
CD4-positive splenocytes from animals previously treated
with anti–IL-17 resulted in no delay in diabetes develop-
ment (anti–IL-17 mean diabetes onset at 41.8 	 4.8 days),
demonstrating that anti–IL-17 treatment does not alter the
CD4-positive T-cell compartment sufﬁciently to regulate
effector diabetogenic splenocytes. In contrast, CD4-posi-
tive splenocytes harvested from animals previously
A
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against diabetogenic splenocytes, resulting in diabetes
prevention in 70% of reconstituted recipients by 80 days
post-transfer (Fig. 6D).
Based on the results obtained in these adoptive transfer
studies, further experiments were conducted to character-
ize the splenic- and pancreatic lymph node–derived lym-
phocyte populations in animals previously treated with
either anti–IL-17 or Il-25. Flow cytometric analysis of these
different lymphocyte sources revealed a signiﬁcant in-
crease in CD4/CD25/Foxp3-positive Treg cells compared
with vehicle-treated controls (Fig. 7), whereas no differ-
ence in the relative frequency of CD8-positive T-cells was
observed (data not shown). To further understand the
function of these lymphocytes, splenic- and pancreatic
lymph node–derived lymphocytes were incubated with
GAD65 for 48 h, and afterward the supernatant was
assayed for TGF-1 activity, a key cytokine that drives
expansion of the Treg cell population. Data in Fig. 7C
demonstrate that prior treatment with either anti–IL-17 or
IL-25 resulted in a signiﬁcant increase in TGF-1 activity
from pancreatic lymph node lymphocytes, with IL-25 treat-
ment resulting in greater TGF-1 activity even when
compared with animals previously treated with anti–IL-17.
No difference in TGF-1 activity was observed among
splenocyte populations within the three treatment groups.
Taken together, these experiments indicate that IL-25
treatment alters the T-cell repertoire in NOD mice, reduc-
ing the frequency of autoreactive GAD65-responsive Th2
and Th17 cells and promoting the development of a
dominantly protective CD4-positive T-cell population with
a relative enrichment in Treg cell populations.
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7 diabetic
splenocytes with no CD4 supplementation (control). Animals were monitored three times per week thereafter for diabetes onset. Supplemen-
tation with CD4-positive cells harvested from mice previously treated with IL-25 resulted in a signiﬁcant dominant protective effect, preventing
diabetes development in 75% of the animals in this group (P < 0.005 vs. anti–IL-17 and control by log-rank). Supplementation with CD4-positive
cells from animals previously treated with anti–IL-17 had no effect, with 100% of the animals becoming diabetic within 60 days post-transfer,
which was comparable to the diabetes incidence observed in the control group.
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The recently characterized pathogenic Th17 population
has been linked to a number of organ-speciﬁc autoimmune
diseases (29) and is currently being investigated as a
clinical therapeutic target in autoimmunity. The current
study demonstrates for the ﬁrst time that inhibition of
Th17 cells, either with neutralizing anti–IL-17 or with
recombinant IL-25, can impact the course of diabetes in
NOD mice, indicating that the Th17 population is a major
contributing factor in this model. Initially, the impact of
these treatments was investigated in two age-groups that
correlate with different stages in the development of
autoimmunity. The impact on diabetes was most evident
when treatment with anti–IL-17 or IL-25 was introduced
during the active phase of autoimmunity preceding the
development of overt disease. The observation that these
treatments could reduce autoimmune -cell destruction
was conﬁrmed by scoring of insulitis and measurement of
GAD65 autoantibodies, which was signiﬁcantly reduced in
both anti–IL-17– and IL-25–treated animals. Taken to-
gether, these data indicate that the Th17 population is less
involved in the initiation of autoimmune diabetes and
primarily contributes to the active phase of disease devel-
opment in this model.
Further characterization of the peri-islet T-cell inﬁltrates
revealed that both anti–IL-17 and IL-25 treatments reduced
the degree of CD4- and CD8-positive inﬁltrates while
increasing the proportion of Foxp3-positive cells, a marker
of the Treg cell population (Fig. 3). These data were
conﬁrmed by ﬂow cytometric analysis of splenocytes and
pancreatic lymph node lymphocytes, which revealed that
either treatment resulted in a relative increase in the Treg
cell population (Fig. 7). Interestingly, the frequency of
Th17 cells within the pancreas was very low at all stages of
disease, with only a small fraction of the peri-islet mono-
nuclear cell inﬁltrate staining positive for IL-17, the char-
acteristic marker of this population (Fig. 3). We observed
that treatment with anti–IL-17 reduced the frequency of
peri-islet IL-17–positive cells even further, whereas treat-
ment with IL-25 resulted in no identiﬁable IL-17–positive
inﬁltrating cells (Fig. 3). The relatively low frequency of
Th17 cells within the insulitic lesions suggests that this
population is more involved in directing an immune re-
sponse in the secondary lymphoid tissues rather than
participating directly in -cell destruction. This concept is
supported by data using the EAE model, which demon-
strates that pathogenic Th17 cells facilitate the develop-
ment of autoreactive effector T-cells during antigenic
priming within cervical draining lymph nodes and that the
Th17 population remains dominant within this compart-
ment throughout the course of disease (30,31). Our ﬁnding
that inhibition of Th17 cells with anti–IL-17 or IL-25 leads
to enrichment in peri-islet Foxp3-positive cells and pan-
creatic lymph node lymphocytes is also consistent with
the Th17/Treg paradigm because it is known that these
populations exert mutually opposing effects (7). Thus, our
data suggest that inhibition of Th17 cells allows the Treg
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of autoimmunity in this model.
To explore the impact of Th17 inhibition on the autoim-
mune response in more detail, B- and T-cell reactivity to
the later-stage autoantigen GAD65 was analyzed (27).
Previous treatment with either anti–IL-17 or IL-25 pre-
vented GAD65 autoantibody formation, and this effect was
durable over time (Fig. 4). This result is in keeping with
data generated in a mouse model of inducible autoimmune
myasthenia gravis, which demonstrated that IL-17 knock-
out animals are resistant to autoantibody formation pri-
marily as a result of the loss of help signals from Th17 cells
during the generation of autoreactive B-cells (32). Data in
the current study also indicate that inhibition of the Th17
population resulted in a similar effect in autoreactive
T-cells. Ex vivo analysis of splenocytes from animals
previously treated with anti–IL-17 or IL-25 using ELISpot
assays established that inhibition of Th17 cells alters the
frequency of GAD65-responsive T-cell populations (Fig. 6).
Surprisingly, no difference was observed in the frequency
of GAD65-responsive IFN-–secreting splenocytes be-
tween both treatment groups and controls, despite the
marked difference in disease outcomes as observed in Fig.
1. Our data indicate that treatment with these Th17-
inhibitory therapies resulted in enrichment in Treg cell
populations, which likely control the pathogenic effects of
autoreactive Th1 cells in the vicinity of the islet.
As expected, treatment with IL-25 signiﬁcantly reduced
the frequency of GAD65-responsive IL-17–secreting cells
(Fig. 6C), which is consistent with previous studies illus-
trating that this cytokine can inhibit formation of the Th17
population (18). The opposite effect was observed in
splenocytes harvested from animals previously treated
with anti–IL-17, which possessed a signiﬁcant increase in
the number of GAD65-responsive IL-17–secreting cells
(Fig. 6C). The relative importance of this expanded Th17
population in these anti–IL-17–treated animals is unclear
because this treatment prevented diabetes development
(Fig. 1B). A possible explanation for these data are the
ﬁndings that IL-17 secretion exerts autocrine and para-
crine effects on Th17 cells, sending a negative feedback
signal to inhibit proliferation (33). Thus, IL-17 neutraliza-
tion could in theory remove that negative signaling event
and enhance the development of Th17 cells. If this were
the only effect of anti–IL-17 treatment, one would antici-
pate that autoimmunity would be accelerated in treated
animals, rather than prevented, as shown in this study and
others (9,14,15). Another possibility involves the “Sprent
effect,” where anticytokine monoclonal antibody treat-
ment paradoxically results in enhanced receptor signaling
(34). Further investigation of the mechanism of anti–IL-17
therapy on autoimmunity in animal models and ongoing
clinical trials will likely reveal the dominant pathway
involved in modulation of autoimmunity using this
approach.
The most intriguing ﬁnding in the current study relates
to the potent effect of IL-25 treatment on the mature
autoimmune response in NOD mice after the onset of
hyperglycemia. It is well known that therapeutic interven-
tions that can prevent diabetes in this model rarely medi-
ate late-stage autoimmunity, resulting in reversal of
disease (28). We explored the impact of both anti–IL-17
and IL-25 treatment using two different models of mature
autoimmune responses, either immediately after disease
onset or after a period of rest and subsequent syngeneic
islet transplantation. As shown in Fig. 5, IL-25 therapy
restored normoglycemia in newly diabetic animals and
signiﬁcantly delayed recurrent autoimmunity after islet
transplantation, whereas anti–IL-17 had no effect in either
setting. These ﬁndings were particularly surprising given
the short serum half-life of IL-25 after subcutaneous injec-
tion, with a peak concentration at 1 h and no detectable
levels by 6 h postinjection (see supplemental Fig. A1,
available in an online appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db08–1113/DC1). It is
likely that the therapeutic effect of IL-25 treatment persists
longer because it inhibits Th17 populations and thus may
result in a protracted immunological impact. Measuring
this effect ex vivo after IL-25 treatment directly would be
challenging; however, adoptive transfer studies using CD4-
positive splenocytes harvested from animals previously
treated with IL-25 indicated that IL-25 induces the forma-
tion of a dominant protective T-cell population that can
control the mature autoimmune response, even after treat-
ment withdrawal (Fig. 6D). Our data indicate that this
result was likely due to a reduction in Th17 cells, expan-
sion of Treg cells, and/or a combination of both effects.
That anti–IL-17 had no effect on the mature autoimmune
response in the current study is not all that surprising,
given that it only neutralizes the effector molecule of the
Th17 population without sending any direct negative sig-
nals. Thus, if the Th17 population has already developed
and expanded, neutralizing the effector molecule IL-17 will
have minimal impact on the course of disease. In fact, as
mentioned previously, IL-17 has been shown to exhibit
negative feedback to the Th17 population (33), so neutral-
izing this cytokine at later disease points may be
disadvantageous.
In summary, the current study indicates that the Th17
population is involved in the pathogenesis of autoimmune
diabetes in the NOD mouse and that intervention with
treatments that inhibit this subset can alter the course of
disease, even after the autoimmune response has evolved
into overt diabetes. Based on these data, further explora-
tion of this subset in the NOD model and in patients with
type 1 diabetes is warranted. The current study also
indicates that further ongoing development of agents like
IL-25 that can directly inhibit the Th17 population will be
superior to approaches using IL-17 neutralization in auto-
immune diabetes. Whereas recombinant IL-25 may not
represent the best therapeutic molecule because of its
short half-life and potential role in allergic airway inﬂam-
mation (35), this study and others provide proof of con-
cept that this therapeutic target should be developed
further for use in autoimmune disease (18).
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